Retatrutide has emerged as a new pharmaceutical in the fight against obesity. This novel drug, belonging to a dual GLP-1 and GIP receptor agonist, exhibits promising results in investigations. By activating these receptors, Retatrutide suppresses appetite, {promotesglucose regulation, and ultimately